Orforglipron is an investigational medication currently being studied for weight loss and type 2 diabetes. Unlike injectable GLP-1 medications, Orforglipron is taken orally and has shown encouraging early results.1 However, it is still in clinical trials and is not available in pharmacies and is not available using PlushCare.*
*Please note that Orforglipron® is still in clinical trials and not yet available in pharmacies or through PlushCare. PlushCare cannot enroll patients in this trial Learn more about our medical weight loss programs, including weight loss medications for qualifying patients. Prescriptions are provided at the doctor’s discretion. Learn more about our controlled substances policy and our prescription discount card.
Orforglipron is a GLP-1 receptor agonist developed by Eli Lilly1. It is being studied for its ability to help with weight loss and blood sugar control in adults with obesity or type 2 diabetes. What sets it apart from existing GLP-1 medications is that it is taken orally, rather than via injection.
Like other GLP-1 receptor agonists, Orforglipron works by mimicking a hormone that targets areas of the brain involved in appetite regulation and blood sugar control. It slows gastric emptying, increases feelings of fullness, and enhances insulin secretion, all of which contribute to reduced calorie intake and improved glycemic control3.
In early clinical trials, participants taking Orforglipron experienced significant weight loss compared to those taking a placebo1. While results are promising, more research is needed to determine the long-term safety and effectiveness of this medication.
In the latest Phase 3 trial, participants taking Orforglipron lost up to 14.7% of their body weight after 36 weeks. This positions Orforglipron as a strong oral competitor to injectable GLP-1 drugs like Wegovy® and Zepbound®.1
As of early 2024, Orforglipron is in Phase 3 clinical trials for both obesity and type 2 diabetes2. These trials are testing different dosages and treatment durations to better understand its potential impact. Participation is limited to clinical trial sites and eligibility requirements are determined by the trial organizers. PlushCare cannot assist in getting into clinical trials.
While data are still limited, side effects reported in trials so far are similar to other GLP-1 medications3:
Vomiting
As with all medications, side effects may vary from person to person and should be monitored closely during trials.
While Orforglipron is not yet available, several other GLP-1 medications are FDA-approved for weight loss and type 2 diabetes treatment.
No. Orforglipron is not approved by the FDA and is only available to participants in clinical trials. PlushCare does not prescribe this medication.
Orforglipron is being studied in adults with obesity or overweight individuals with at least one weight-related condition. In the latest trials, participants had an average BMI of 37 and were mostly women with a median age of 50.
Orforglipron is the first oral non-peptide GLP-1 receptor agonist in development for FDA approval to treat weight loss, which could make it more convenient than injectable alternatives 1. It may also serve as a more effective oral GLP-1 than Rybelsus – the other current oral GLP-1 – for treating diabetes.
If approved, Orforglipron will initially be available as a brand-name drug only. Generic versions typically become available after patent protections expire.
Yes. In addition to weight loss, Orforglipron is being studied for blood sugar control in type 2 diabetes2.
PlushCare is dedicated to providing you with accurate and trustworthy health information.
PlushCare content is reviewed by MDs, PhDs, NPs, nutritionists, and other healthcare professionals. Learn more about our editorial standards and meet the medical team. The PlushCare site or any linked materials are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment.
